Form 4: Bicycle Therapeutics Officer Sells Shares for Tax

Bicycle Therapeutics' Chief Accounting Officer, Travis Thompson, sold shares to cover tax obligations from restricted stock unit vesting.

Summary

• Travis Thompson, Chief Accounting Officer of Bicycle Therapeutics PLC (BCYC), reported sales of ordinary shares.
• On October 2, 2025, 221 ordinary shares were sold at a weighted average price of $8.40 per share, with prices ranging from $8.37 to $8.45.
• On October 3, 2025, an additional 103 ordinary shares were sold at a weighted average price of $8.41 per share, with prices ranging from $8.40 to $8.50.
• These sales were non-discretionary, mandated by the reporting person's award agreement to satisfy statutory tax withholding obligations upon the vesting and settlement of restricted stock units.
• Following these transactions, Thompson beneficially owns 31,197 ordinary shares directly.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations related to RSU vesting, not indicative of discretionary insider selling or buying, thus having a neutral sentiment impact.

Positives

• NA The transaction is a routine 'sell to cover' for tax obligations and does not inherently present positive news for the company's operational or financial performance.

Negatives

• NA The transaction is a routine 'sell to cover' for tax obligations and does not indicate a lack of confidence from the reporting person or negative operational news for the company.

Risks

• NA This Form 4 filing does not detail company-specific risks.

Future Outlook

NA This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• NA The filing contains no direct quotes or paraphrased statements from company management, beyond the signature confirming the transaction details.

Industry Context

NA This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• NA This filing is a standard Form 4 for an insider transaction and does not contain information suitable for comparison to global industry benchmarks or specific comparable companies/projects.

Management Changes

Corporate Governance

Legal Proceedings

• NA This filing does not mention any litigation or regulatory matters.

Related Party Transactions

• NA This filing does not disclose any related party dealings beyond the executive's compensation-related share transactions.

Stakeholder Impact

• Minimal impact on shareholders as the sale is non-discretionary and for tax purposes, not indicative of a change in company outlook or management confidence.
• No direct impact on employees, customers, suppliers, or creditors is implied by this filing.

Next Steps

• NA The filing does not mention any future actions, events, or milestones.

Key Dates

Recommendation

The reported sales by the Chief Accounting Officer are non-discretionary 'sell to cover' transactions to satisfy tax obligations from restricted stock unit vesting. This is a routine event and does not reflect a change in management's confidence or the company's fundamentals, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Share Sale, Restricted Stock Units, Tax Withholding, Travis Thompson, Chief Accounting Officer